MacroGenics (MGNX)

• Market cap: $93.6M
• 1 day: 2.07%
• 5 days: 3.5%
• 1 month: -22.51%
• 3 months: -18.23%
• 6 months: -0.67%
• Year to date: -55.15%
• 1 year: -56.47%
• 5 years: -93.58%
• 10 years: -95.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341